243 related articles for article (PubMed ID: 26513296)
1. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.
Kelly KR; Espitia CM; Zhao W; Wendlandt E; Tricot G; Zhan F; Carew JS; Nawrocki ST
Oncotarget; 2015 Dec; 6(38):41275-89. PubMed ID: 26513296
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
Sborov DW; Nuovo GJ; Stiff A; Mace T; Lesinski GB; Benson DM; Efebera YA; Rosko AE; Pichiorri F; Grever MR; Hofmeister CC
Clin Cancer Res; 2014 Dec; 20(23):5946-55. PubMed ID: 25294913
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
Stiff A; Caserta E; Sborov DW; Nuovo GJ; Mo X; Schlotter SY; Canella A; Smith E; Badway J; Old M; Jaime-Ramirez AC; Yan P; Benson DM; Byrd JC; Baiocchi R; Kaur B; Hofmeister CC; Pichiorri F
Mol Cancer Ther; 2016 May; 15(5):830-41. PubMed ID: 26809490
[TBL] [Abstract][Full Text] [Related]
4. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.
Kelly KR; Espitia CM; Mahalingam D; Oyajobi BO; Coffey M; Giles FJ; Carew JS; Nawrocki ST
Oncogene; 2012 Jun; 31(25):3023-38. PubMed ID: 22002308
[TBL] [Abstract][Full Text] [Related]
5. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
Carew JS; Espitia CM; Zhao W; Kelly KR; Coffey M; Freeman JW; Nawrocki ST
Cell Death Dis; 2013 Jul; 4(7):e728. PubMed ID: 23868061
[TBL] [Abstract][Full Text] [Related]
6. Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.
van den Wollenberg DJ; Dautzenberg IJ; van den Hengel SK; Cramer SJ; de Groot RJ; Hoeben RC
PLoS One; 2012; 7(10):e48064. PubMed ID: 23110175
[TBL] [Abstract][Full Text] [Related]
7. Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.
Kawagishi T; Kanai Y; Nouda R; Fukui I; Nurdin JA; Matsuura Y; Kobayashi T
J Virol; 2020 Nov; 94(23):. PubMed ID: 32907973
[TBL] [Abstract][Full Text] [Related]
8. Reovirus modulates autophagy during oncolysis of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Autophagy; 2013 Mar; 9(3):413-4. PubMed ID: 23322106
[TBL] [Abstract][Full Text] [Related]
9. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures.
van den Hengel SK; Balvers RK; Dautzenberg IJ; van den Wollenberg DJ; Kloezeman JJ; Lamfers ML; Sillivis-Smit PA; Hoeben RC
Cancer Gene Ther; 2013 Sep; 20(9):507-13. PubMed ID: 23907517
[TBL] [Abstract][Full Text] [Related]
11. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts.
Hingorani P; Zhang W; Lin J; Liu L; Guha C; Kolb EA
Cancer; 2011 Apr; 117(8):1764-74. PubMed ID: 21472724
[TBL] [Abstract][Full Text] [Related]
12. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
[TBL] [Abstract][Full Text] [Related]
13. JAM-A expression positively correlates with poor prognosis in breast cancer patients.
McSherry EA; McGee SF; Jirstrom K; Doyle EM; Brennan DJ; Landberg G; Dervan PA; Hopkins AM; Gallagher WM
Int J Cancer; 2009 Sep; 125(6):1343-51. PubMed ID: 19533747
[TBL] [Abstract][Full Text] [Related]
14. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
Shmulevitz M; Lee PW
Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
[TBL] [Abstract][Full Text] [Related]
15. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus.
Harryvan TJ; Golo M; Dam N; Schoonderwoerd MJA; Farshadi EA; Hornsveld M; Hoeben RC; Hawinkels LJAC; Kemp V
Cancer Gene Ther; 2022 Dec; 29(12):1918-1929. PubMed ID: 35869278
[TBL] [Abstract][Full Text] [Related]
17. Endothelial JAM-A promotes reovirus viremia and bloodstream dissemination.
Lai CM; Boehme KW; Pruijssers AJ; Parekh VV; Van Kaer L; Parkos CA; Dermody TS
J Infect Dis; 2015 Feb; 211(3):383-93. PubMed ID: 25149763
[TBL] [Abstract][Full Text] [Related]
18. Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Apoptosis; 2016 Dec; 21(12):1422-1437. PubMed ID: 27734217
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of oncolytic reovirus against human breast cancer cells.
Hata Y; Etoh T; Inomata M; Shiraishi N; Nishizono A; Kitano S
Oncol Rep; 2008 Jun; 19(6):1395-8. PubMed ID: 18497942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
